LaBarge (US) moves to transdermal delivery trials:
This article was originally published in Clinica
LaBarge (US) has received US FDA permission to undertake trials of its Laser Lancet transdermal drug delivery technology. Preclinical research has shown that the system can significantly increase the permeability of skin to insulin, interferon and hydrocortisone, the company says. The Laser Lancet has also been used to improve the onset of lidocaine local anaesthesia.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.